• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    The role of Hepatic 11-β hydroxysteroid dehydrogenase Type 1 in Uraemia-induced Insulin Resistance. 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • The role of Hepatic 11-β hydroxysteroid dehydrogenase Type 1 in Uraemia-induced Insulin Resistance.
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • The role of Hepatic 11-β hydroxysteroid dehydrogenase Type 1 in Uraemia-induced Insulin Resistance.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    The role of Hepatic 11-β hydroxysteroid dehydrogenase Type 1 in Uraemia-induced Insulin Resistance.

    View/Open
    Chapagain_Ananda_PhD_Final_170316.pdf (3.109Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    Insulin resistance and associated metabolic sequelae are common in Chronic Kidney Disease (CKD) and are positively and independently associated with increased cardiovascular mortality. However, the pathogenesis has yet to be fully elucidated. 11β-Hydroxysteroid Dehydrogenase type 1 (11β-HSD1) catalyses intracellular regeneration of active glucocorticoids, promoting insulin resistance in liver and other metabolic tissues. Using data from two experimental rat models of CKD (subtotal nephrectomy and adenine diet) which show early insulin resistance, we found that 11β-HSD1 mRNA and protein increase in hepatic and adipose tissue, together with increased hepatic 11β-HSD1 activity. This was associated with intrahepatic but not circulating glucocorticoid excess, and increased hepatic gluconeogenesis and lipogenesis. Oral administration of the 11β-HSD inhibitor carbenoxolone to uraemic rats for 2 weeks improved glucose tolerance and insulin sensitivity, improved insulin signalling, and reduced hepatic expression of gluconeogenic and lipogenic genes. Furthermore, 11β-HSD1−/− mice and rats treated with a specific 11β-HSD1 inhibitor (UE2316) were protected from metabolic disturbances despite similar renal dysfunction following adenine-induced experimental uraemia. Therefore, we demonstrate that elevated hepatic 11β-HSD1 is an important contributor to early insulin resistance and dyslipidaemia in uraemia. Specific 11β-HSD1 inhibitors potentially represent a novel therapeutic approach for management of insulin resistance in patients with CKD.
    Authors
    Chapagain, Ananda
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/12581
    Collections
    • Theses [3321]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.